Metraipolis › archive › dc_ffefc68e4f6b

Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis with stage 3-5 chronic kidney disease: a retrospective real-world study — Europe PMC PMID:42806983

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42806983
DOI
10.3389/fmed.2026.1906235
License (as archived)
solo-consultazione
Archived
2026-10-08T17:18:29.266Z
SHA-256 of the archived text
58d355e0061b34ea9b20d9ced44f76bc7261c7739e18d0c8610f58ed6d70e0e2
Stable URL of this page
https://metraipolis.com/documento/dc_ffefc68e4f6b

How to cite

Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis with stage 3-5 chronic kidney disease: a retrospective real-world study — Europe PMC PMID:42806983 — Europe PMC (en), https://europepmc.org/article/MED/42806983 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ffefc68e4f6b (Metraipolis archive dc_ffefc68e4f6b, sha256 58d355e0061b34ea9b20d9ced44f76bc7261c7739e18d0c8610f58ed6d70e0e2)
BibTeX
@misc{dcffefc68e4f6b,
  title = {Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis with stage 3-5 chronic kidney disease: a retrospective real-world study — Europe PMC PMID:42806983},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42806983},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ffefc68e4f6b; sha256 58d355e0061b34ea9b20d9ced44f76bc7261c7739e18d0c8610f58ed6d70e0e2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42806983. Agents can read the archived copy with the MCP tool read_document.